Dr. Rizvi on Utilizing Molecular Characteristics to Inform Treatment Decisions in NSCLC


In Partnership With:

Naiyer A. Rizvi, MD, discusses treatment approaches in non–small cell lung cancer.

Naiyer A. Rizvi, MD, Price Family ​Professor of ​Medicine, director, Thoracic Oncology, co-director, Cancer Immunotherapy, Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, research director, Price Family Comprehensive Center for Chest Care, NewYork-Presbyterian Hospital, discusses treatment approaches in non–small cell lung cancer (NSCLC). 

​Therapy for patients with NSCLC should be individualized ​and selected based on molecular ​abnormalities and PD-L1 status, says Rizvi.

However, patients with high PD-L1 expression and an EGFR mutation should receive targeted therapy rather than immunotherapy as oncogenic drivers are preferred to PD-L1 status, Rizvi explains. 

Moreover, in an era where numerous plasma​-based assays are receiving regulatory approval, molecular data should be thoroughly evaluated to inform treatment decisions before they are made, Rizvi concludes. 

Related Videos
J. Randolph (Randy) Hecht, MD
Qian (Janie) Qin, MD
Ajai Chari, MD
Jonathan Wesley Riess, MD, MS, an associate professor at the University of California (UC) Davis
Joachim G. J. V. Aerts, MD, PhD
Key opinion leaders from across the hematologic oncology realm shared their biggest takeaways from the 2023 SOHO Annual Meeting.
Naval G. Daver, MD
Pasi A. Jänne, MD, PhD
Saad Z. Usmani, MD, MBA, FACP
Related Content